Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2014 /PRNewswire/ ... announced that Bonnie H. Anderson , president and chief ... the Piper Jaffray 26 th Annual Healthcare Conference on ... New York . The live audio ... website at http://investor.veracyte.com . Please connect to the website ...
(Date:11/24/2014)... Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. ... both in the United States District Court for ... . On November 21, 2014 ...
(Date:11/22/2014)... 21, 2014 Prominent academics, leaders ... gather on December 3rd at Genetic Rx, a ... GeneticRx will take place at the Joseph B. ... will discuss the present and future of genetic ... and gene editing—as well as the treatment of ...
(Date:11/22/2014)... 2014 Respiratory therapy students will ... management of life-like respiratory ailments using the latest ... Grand Rapids-based, Michigan Instruments Inc. developers of the ... the respiratory simulation units to the pro-gram, which ... and Muskegon Community College are collaborating to offer ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... ExL Pharma is pleased to announce the,fall ... leading issues that are,impacting the pharmaceutical industry today. ... networking opportunities for Clinical,Marketing, R&D, and Medical Affairs ... technology companies. Listed below are details on ...
... Tools Experience to the Leader in ... Cellular Bioenergetic Profiling, N. ... tools for real-time measurement of cellular,bioenergetics in microplates, announced today ... the company,s Board of,Directors. In this position, Keegan will apply ...
... PhD, Further Strengthens Kendle,s Global ... Regulatory Affairs Organization, ... ), a,leading, global full-service clinical research organization, today,announced that ... Affairs Consultant specializing in providing regulatory affairs,guidance to the ...
Cached Biology Technology:Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 2Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant 3
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/15/2014)... we may still be a few years away from the ... gain instant access to all that ailed his patients, mobile ... for monitoring and measuring our health are cropping up in ... tad Orwellian to some, but a new survey suggests that ... into their healthcare regime. These are some of ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... MARC (Maximizing Access to Research Careers) Program has announced ... Conferences held in July, 2013. These awards are meant ... and scientists into the mainstream of the basic science ... at the FASEB Science Research Conferences. This year MARC ...
... MARC (Maximizing Access to Research Careers) Program has announced ... Study of Reproduction meeting in Montreal, Canada from July ... entry of students, postdoctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ...
... 2011 and 2012, research from China,s Nanjing University made ... of genetic material from the plants they,d ingested could ... animals, own genes off. The surprising results from Chen-Yu ... one day be treated with medicinal food, but also ...
Cached Biology News:Hold the medicinal lettuce 2Hold the medicinal lettuce 3
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
SH3 Proteins II Sampler Kit 10g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Human peripheral blood eosinophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: